Why Is Pfizer (PFE) Facing Fresh Global mRNA Patent Lawsuits?
Why Is Pfizer (PFE) Facing Fresh Global mRNA Patent Lawsuits? Simply Wall St
Covered in this story
Analyst targets on Pfizer
- Cantor Fitzgerald: at $28.3 · target $28 by Oct 2027 · Neutral via TIKR.com
- Bank of America: at $28.3 · target $29 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: at $28.3 · target $30 by Oct 2027 · Neutral via The Globe and Mail
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 47 stories mentioning Pfizer, the earliest published 2 Mar 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.